Valganciclovir Hydrochloride 900mg Extended-Release Tablets from Japan
High-dose 900mg extended-release tablets of valganciclovir HCl for once-daily CMV prophylaxis in transplant recipients. Falls under HTS 3004.90.92.05 as specified antiviral in measured retail doses despite modified release profile.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Submit in vitro/in vivo correlation data for extended-release classification
• Ensure batch dissolution testing meets USP specifications
• Label clearly as extended-release to avoid confusion with immediate-release forms